Naptumomab

Naptumomab

Sök

    Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading

    Meir Azulay, Michal Shahar, Eitan Shany, Eti Elbaz, Sveta Lifshits, Marie Törngren, Adam Friedmann, Robert Kramer & Gunnar Hedlund

    Journal of Translational Medicine 2023 21:222

    Läs artikeln här

    Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer

    Hossein Borghaei, Katherine Alpaugh, Gunnar Hedlund, Göran Forsberg, Corey Langer, Andre Rogatko, Robert Hawkins, Svein Dueland, Ulrik Lassen, Roger B Cohen

    J Clin Oncol. 2009 Sep 1; 27 (25): 4116-23

    Selective T cell Redirection Proteins (STR) Enhance the Anti-Tumor Activity of Checkpoint Inhibitors (CPIs) and can Lead to Long-Lasting Immunity Againstthe Tumor

    Meir Azulay, Sveta Lifshits, EitanShany, Adam Friedmann, Gunnar HedlundandMichal Shahar

    NeoTXTherapeuticsLTD, Rehovot, Israel

    Läs postern här

    Naptumomab Estafenatox induces T cell recognition, turning anti-PD-1 unresponsive ”cold” tumors into ”hot” responsive tumors

    Azulay M, Lifshits S, Fridman A, Hedlund G, Törngren M, Shahar M

    Poster presentation at AACR Annual Meeting 2018

    Läs postern här

    A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis

    Hawkins R, Gore M, Shparyk Y, Bondar V, Gladkov O, Ganev T, Harza M, Polenkov S, Bondarenko I, Karlov P, Karyakin O, Khasanov R, Hedlund G, Forsberg G, Nordle Ö, Eisen T

    Clin Cancer Res. 2016; 22(13): 3172-81

    Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α

    Elkord E, Burt DJ, Sundstedt A, Nordle Ö, Hedlund G, Hawkins R

    Oncotarget. 2015; 6(6): 4428-39

    Naptumomab Estafenatox: targeted Immunotherapy with a Novel Immunotoxin

    Eisen T, Hedlund G, Forsberg G, Hawkins R

    Curr Oncol Rep. 2014; 16: 370

    The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity

    Hedlund G, Eriksson H, Sundstedt A, Forsberg G, Jakobsen BK, Pumphrey N, Rödström K, Lindkvist-Petersson K, Björk P

    PLoS One. 2013; 8(10): e79082

    Monotherapeutically Nonactive CTLA-4 Blockade Results in Greatly Enhanced Antitumor Effects When Combined With Tumor-targeted Superantigens in a B16 Melanoma Model

    Sundstedt A, Celander M, Eriksson H, Törngren M, Hedlund G

    J Immunother. 2012; 35(4): 344–53

    Tumor-Targeted Superantigens, in Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

    Hedlund G, Forsberg G, Nederman T, Sundstedt A, Dahlberg L, Tiensuu M, Nilsson, M

    (ed S. R. Schmidt) 2013; p365-381, John Wiley & Sons, Inc., Hoboken, NJ, USA